Find clinical trials for Eczema in New York, NY

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Atopic Dermatitis

Dermatitis

Skin Diseases

Immune System Diseases

Eczematous Skin Diseases

Food Hypersensitivity

Genetic Skin Diseases

Eczema trials near New York, NY, USA:

A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema. People with this condition may have ...

Enrolling

Eczema, Atopic

Atopic Dermatitis

Drug: PF-08049820

Drug: Placebo

Phase 2

Pfizer

The Bronx, New York, United States and 41 other locations

Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis

The purpose of this study is to evaluate the safety and efficacy of long-term treatment with IMG-007 in participants with moderate-to-severe atopic d...

Invitation-only

Atopic Dermatitis Eczema

Eczema

Drug: IMG-007

Phase 2

Inmagene

New York, New York, United States and 22 other locations

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis (ADAPTIVE)

The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.

Enrolling

Atopic Dermatitis Eczema

Eczema

Drug: Placebo

Drug: IMG-007

Phase 2

Inmagene

New York, New York, United States and 39 other locations

A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.

Enrolling

Eczema Atopic Dermatitis

Eczema, Atopic

Drug: Camoteskimab

Drug: Placebo

Phase 2

Apollo Therapeutics

New York, New York, United States and 84 other locations

Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234

This is a first-in-human, Phase 1, double-blind, randomized, placebo-controlled, dose-escalation study evaluating ARQ-234. The study is designed to a...

Enrolling

Eczema

Atopic Dermatitis (AD)

Drug: Placebo

Biological: ARQ-234

Phase 1

Arcutis Biotherapeutics

Fair Lawn, New Jersey, United States and 6 other locations

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-1)

The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18...

Active, not recruiting

Eczema

Atopic Dermatitis

Drug: Placebo

Drug: Lebrikizumab

Phase 3

Lilly

East Windsor, New Jersey, United States of America and 88 other locations

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis (COMPASS 2-AD)

This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB75...

Active, not recruiting

Atopic Dermatitis (AD)

Biological: BFB759

Drug: Placebo

Phase 2

Bluefin Biomedicine, Inc.

New York, New York, United States and 88 other locations

ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis

This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.

Active, not recruiting

Eczema

Atopic Dermatitis

Drug: ATI-045

Drug: Placebo

Phase 2

Aclaris Therapeutics

New York, New York, United States and 60 other locations

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

This is a Phase 1b, randomized, placebo/vehicle-controlled, double-blinded, multi-center trial. It is designed to assess the safety and efficacy of S...

Enrolling

Atopic Dermatitis

Drug: Fluocinonide Ointment

Drug: Clobetasol Ointment

Phase 1